News Blow for MSD as NICE rejects Keytruda in first line lung can... Firm will have to offer further discount to get drug to NHS patients.
News EU green light for Novartis combo in lung cancer Tafinlar and Mekinist looks set for approval in BRAF V600 lung cancer
News Novartis' Zykadia gets fast first-line lung cancer review Roche rival has Breakthrough Therapy status.
News Icahn takes stake in BMS, adding to takeover speculation Activist investor's intervention adds to buzz surrounding BMS.
News BMS suffers further setback in lung cancer No fast approval for immunotherapy combo in first line use.
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
